CRS and HIPEC in the Treatment of CRC with Peritoneal Metastases
Posted in Lectures on 25 September 2020
Dr. Carolina González-Abós MD
Department of Gastrointestinal Surgery
Hospital Clinic, Barcelona (Spain)
Peritoneal carcinomatosis (PC) is a common disease with poor prognosis. From colorectal carcinoma (CRC) origin, 19% of the patients will metachronically present with PC. These patients usually suffer from cachexia, ascites, and other symptoms that made them very challenging patients. Palliative chemotherapy showed a limited improvement in overall survival despite new target therapies. Cytoreductive surgery (CRS) + Hyperthermic Intraperitoneal Chemotherapy (HIPEC) is the gold standard treatment for selected patients with PC of colorectal origin.